The global apolipoprotein test market was valued at around US$ 503.15 Million at the end of 2021. The market is projected to register a 7.6% CAGR and top a valuation of US$ 1,126.26 Million by 2032.
The growing geriatric population, altered diet and lifestyle patterns, and rising health awareness of various heart diseases are anticipated to propel market expansion in the near future.
Apolipoproteins are proteins that transport by binding to them. There are various different varieties of apolipoproteins, however the main protein forms that come from low-density lipoproteins are apolipoprotein B. (LDL). Apo B exists in humans in two different forms.
While Apo B48 is helpful in the observation of lipid-soluble nutrients and medications, Apo B100 aids in the evaluation of the risk of developing cardiovascular disease. Controlling cardiac problems is the responsibility of apo A and apo c3. Because most adults with high cholesterol have an elevated risk of acquiring cardiovascular illnesses, the apolipoprotein test market is anticipated to grow rapidly.
These examinations are carried out to identify cardiovascular illnesses' early-stage risk factors as early as possible. Due to rising risks of serious cardiac disorders like stroke and heart attack, the apolipoprotein test market is anticipated to rise rapidly.
According to the World Health Organization, heart attacks and strokes account for over 85% of all cardiovascular disease-related deaths, and about 17.9 million individuals worldwide pass away from CVDs each year. The two primary apolipoproteins, apoA and apoB, are primarily linked to CVD.
| Attributes | Details |
| Apolipoprotein Test Market Value in 2021 | US$ 503.15 Million |
| Apolipoprotein Test Market Value in 2032 | US$ 1126.26 Million |
| Apolipoprotein Test Market CAGR (2022 to 2032) | 7.6% |
One of the key factors propelling the growth of the apolipoprotein test market is anticipated to be the rising need for diagnostic services in the developing world. The market for apolipoprotein tests may experience expansion due to increased awareness of the need of maintaining good cardiac health.
Apolipoprotein test demand is being boosted by a variety of major cardiovascular conditions such as coronary heart disease, high blood pressure, cardiac arrest, heart failure, stroke, and arrhythmia, as well as by many other diseases.
Most doctors, heart specialists, and other healthcare professionals now advise people with a personal family history of heart disease to get an apolipoprotein test. As a result, one of the key reasons propelling the market expansion for apolipoprotein testing is the referral of these tests by physicians to patients with a family history of heart disease.
Apolipoprotein testing is another recommendation made by doctors to people with elevated cholesterol levels. People typically perform apolipoprotein tests once or twice a year due to increasing knowledge of the risk of developing cardiac diseases and greater health education, this may also be a factor in the market expansion for apolipoprotein testing.
The apolipoprotein test market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
North America dominated the regional apolipoprotein test market due to the high rates of obesity and high consumption of saturated fats among the people in US. Additionally, people in the USA often have higher expectations for diagnostic services and longer life spans. This is also projected to play a significant role in the market expansion for apolipoprotein tests in the United States.
Moreover, the market for apolipoprotein tests in the Asia-Pacific region is anticipated to expand at a rapid rate due to the rising incidence of CVD and the consequent rise in demand for diagnostic services, particularly given the high rates of heart disease in China and India.
Randox Laboratories Ltd., Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories Inc., OPKO Health Inc., Myriad Genetics Inc., Quest Diagnostics Inc., Eurofins Scientific, Lincoln Diagnostics LLC., DiaSorin S.p.A., Boster Biological Technology, Ltd., and Rockland Immunochemicals Inc.
| Report Attributes | Details |
| Growth Rate | CAGR of 7.6% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, Volume in Units, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segment Covered |
|
| Region Covered |
|
| Key Countries Profiled |
|
| Key Players |
|
| Customization | Available Upon Request |
The global apolipoprotein test market is anticipated to register a CAGR of 7.6% during the forecast period.
Randox Laboratories Ltd., Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories Inc., OPKO Health Inc., Myriad Genetics Inc., Quest Diagnostics Inc., Eurofins Scientific, Lincoln Diagnostics LLC., DiaSorin S.p.A., Boster Biological Technology, Ltd., and Rockland Immunochemicals Inc., among others are some prominent apolipoprotein test market players.
Explore Similar Insights
Apolipoprotein Test Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
